Single Celsius

Third Rock launched Celsius to apply single-cell genomics to drug development

After identifying its first targets, Third Rock Ventures newco Celsius Therapeutics emerged from stealth with a $65 million series A round to apply single-cell genomics techniques to drug development for autoimmune diseases and cancer.

GV, Heritage Provider Network, Casdin Capital, Alexandria Venture Investments and

Read the full 448 word article

User Sign In